The prognostic value of MELD-XI in elderly patients with ST-segment elevation myocardial infarction: an observational study

Song-jian He1†, Jian-xin Weng2†, Hai-jun Chen1, Hua-qiu Li1, Wen-qin Guo1, Qian Cao1, Shuai Xu1, Hong-bing Yan1 and Chang-nong Peng1*

Abstract
Background: The model for end-stage liver disease excluding international normalized ratio (MELD-XI) is a simple score for risk assessment. However, the prognostic role of MELD-XI and its additional value to current risk assessment in elderly patients with ST-segment elevation myocardial infarction (STEMI) undergoing percutaneous coronary intervention (PCI) is uncertain.

Methods: In all, 1029 elderly patients with STEMI undergoing PCI were consecutively included and classified into three groups according to the TIMI risk score: low-risk (≤ 3, n = 251); moderate-risk (4–6, n = 509); and high-risk (≥ 7, n = 269) groups. Multivariate analysis was performed to identify risk factors for adverse events.

Results: The overall in-hospital mortality was 5.3% and was significantly higher in the high-risk group (1.2% vs. 3.3% vs. 13.0%, p < 0.001). The optimal cut-off of the TIMI risk score and MELD-XI for in-hospital death was 7 and 13, respectively. MELD-XI was associated with in-hospital (adjusted odds ratio = 1.09, 95% CI = 1.04–1.14, p = 0.001) and one-year (adjusted hazard ratio = 1.05, 95% CI = 1.01–1.08, p = 0.005) mortality independently of the TIMI risk score. Combining TIMI risk score and MELD-XI exhibited better predictive power for in-hospital death than TIMI risk score (area under the curve [AUC] = 0.810 vs. 0.753, p = 0.008) or MELD-XI alone (AUC = 0.810 vs. 0.750, p = 0.018). Patients with TIMI risk score ≥ 7 and MELD-XI ≥ 13 had the worst prognosis.

Conclusion: MELD-XI could be considered as a risk-stratified tool for elderly patients with STEMI undergoing PCI. It had an additive prognostic value to TIMI risk score.

Keywords: MELD-XI, TIMI risk score, ST-segment elevation myocardial infarction, Percutaneous coronary intervention

Introduction
Early diagnosis and intervention have dramatically improved the prognosis of ST-segment elevation myocardial infarction (STEMI) [1, 2]. However, the mortality from STEMI remains high in elderly patients.

Epidemiological data have indicated that the estimated one-year mortality in elderly patients with STEMI undergoing percutaneous coronary intervention (PCI) is 10% and continues to increase with age [3–5]. The Thrombolysis In Myocardial Infarction (TIMI) risk score is a guideline-recommended, risk-stratified tool for STEMI patients [6]. Nevertheless, this score is not established specially for elderly patients. Previous studies have shown that the area under the curve (AUC) of TIMI risk score was only 0.71 for predicting in-hospital mortality and 0.67 for 30-day mortality [7, 8] in elderly patients with...
STEMI. Therefore, improving the predictive accuracy is necessary for these patients.

Aging represents the progressive functional decline in a variety of organ systems that occurs with advancing time [9]. Renal and liver dysfunction were common in elderly patients with myocardial infarction, which were associated with poor prognosis [10, 11]. The model for end-stage liver disease excluding international normalized ratio (MELD-XI) score is a novel and simple score to simultaneously assess liver and kidney function [12]. This scoring model exhibited excellent predictive power in critically ill patients [13, 14]. However, the association of MELD-XI with adverse events has not been reported in STEMI patients. Therefore, this study was performed to investigate the prognostic value of MELD-XI in elderly patients with STEMI undergoing PCI and determine whether adding MELD-XI to the TIMI risk score enhances the prediction of in-hospital and one-year death.

Methods
Study population
This was a single-center cohort study conducted at Fuwai Hospital Chinese Academy of Medical Sciences, Shenzhen. A total of 1137 elderly patients (≥60 years) with STEMI undergoing PCI were retrospectively screened from January 2010 to December 2018. STEMI was defined according to the European Society of Cardiology guidelines [15]. 108 were excluded for the following reasons: hospital stay < 24 h (n = 23), malignancy (n = 19), aortic dissection (n = 6), requiring coronary artery bypass grafting (n = 31) and without admission data on bilirubin (n = 29). The study protocol was approved by the Ethics Committee of our hospital (SP2017016), and the need for informed consent was waived given the retrospective nature of the analysis.

Measurement and data collection
Serum creatinine and bilirubin were measured at admission. Left ventricular ejection fraction (LVEF) was evaluated by echocardiography within 24 h after admission. The demographic and clinical characteristics were collected from electronic medical records by one researcher and randomly checked by another researcher. The TIMI risk score for patients with STEMI was calculated based on the following characteristics: age; systolic blood pressure (SBP); heart rate; Killip classification; weight; history of angina, diabetes, and/or hypertension; presence of anterior myocardial infarction and/or left bundle branch block presentation; and time to treatment [16]. The MELD-XI score was calculated by using the following formula: 5.11 × (ln total bilirubin, mg/dL) + 11.76 × (ln creatinine, mg/dL) + 9.44 [17].

Follow-up and endpoints
Each patient was followed-up via telephonic interview for one year after a diagnosis of STEMI. We also reviewed the outpatient and re-admission records for possible adverse events. The primary endpoints were in-hospital and one-year all-cause mortality. In addition, the incidence of stroke, dialysis, acute heart failure, and target vessel revascularization (TVR) during the hospitalization period were defined as major adverse clinical events (MACEs).

Statistical analysis
All statistical analyses were performed using SPSS 22.0 (Inc., Chicago, Illinois). Continuous data were expressed as mean ± SD or median (IQR) and compared using the two independent samples t-test or Wilcoxon rank-sum test. Categorical data were shown as frequency and percentage, and compared using the chi-squared test. The predictive value was assessed by AUC obtained through receiver operator characteristic (ROC) curves. The AUC was compared using nonparametric tests [18]. In addition, the optimal cut-off for predicting in-hospital death was recorded. The risk factors of in-hospital and one-year mortality were determined by logistic regression analysis and Cox regression analysis, respectively. All significant variables in the univariate analysis, except the elements of the TIMI risk score, were included in the multivariate analysis. The Kaplan–Meier curve for one-year mortality was plotted and compared using the log-rank test. For all comparisons, p < 0.05 was considered to indicate statistical significance.

Results
In all, 1029 STEMI patients were included, and were divided into three groups according to the TIMI risk score: low risk (≤3, n=251); moderate risk (4–6, n=509); and high risk (≥7, n=269). The clinical characteristics according to different risk status were showed in Table 1. Patients in the high-risk group were more likely to be female. The high-risk group showed higher serum creatinine, alanine transaminase (ALT), and total bilirubin levels and lower hemoglobin and LVEF than the other two groups. The rate of intra-aortic balloon pump (IABP) placement was higher in patients with a high TIMI risk score. In addition, prolonged hospitalization was observed in these patients.

55 (5.3%) patients died while in hospital, 42 of which died from cardiac disease. Other causes of death included infection, cerebral hernia and multiple organ
failure. A higher in-hospital all-cause mortality (1.2% vs. 3.3% vs. 13.0%, p < 0.001), cardiac mortality (1.2% vs. 2.6% vs. 9.7%, p < 0.001) and MACEs (5.6% vs. 10.8% vs. 24.2%, p < 0.001) were found in patients with high TIMI risk score than the low- and medium-risk groups. The ROC curve showed that MELD-XI ≥ 13 had a sensitivity of 63.6% and specificity of 80.2% for predicting in-hospital all-cause death (AUC = 0.750, 95% CI = 0.684–0.816, p < 0.001, Fig. 1). The AUC of TIMI risk score was 0.753 and the optimal cut-off was 7. No statistically significant difference was found on comparing their discriminatory abilities.

Multivariate logistic regression analysis indicated that MELD-XI was independently associated with in-hospital all-cause death even after adjusting for TIMI risk score, log(creatine kinase MB), ALT > 40 U/L, LVEF, and IABP treatment (OR = 1.09, 95% CI = 1.04–1.14, p = 0.001, Table 2). A similar result was seen when we included MELD-XI ≥ 13 instead of MELD-XI as a continuous variable in model 2 (OR = 3.83, 95% CI = 1.99–7.40, p < 0.001, Table 2). Therefore, we added four points into the TIMI risk score when MELD-XI ≥ 13 according to the adjusted OR. Combining TIMI risk score and MELD-XI exhibited better predictive power for in-hospital all-cause death than the TIMI risk score (AUC: 0.810 vs. 0.753, p = 0.008, Fig. 1a) or MELD-XI alone (AUC: 0.810 vs. 0.750, p = 0.018, Fig. 1a). Similar result was found in cardiac mortality (Fig. 1b).

In total, 109 (10.6%) patients died during the one-year follow-up period. Multivariate Cox regression analysis showed that MELD-XI was a predictor for one-year mortality independent of the TIMI risk score (HR = 1.17, 95% CI = 1.03–1.34, p = 0.017). Combining TIMI risk score and MELD-XI exhibited better predictive power for one-year mortality than the TIMI risk score alone (HR: 1.16 vs. 0.97, p = 0.038, Fig. 1b).

### Table 1 Clinical characteristics according to different risk status

| Variable                        | Low-risk group (≤ 3, n = 251) | Moderate-risk group (4–6, n = 509) | High-risk group (≥ 7, n = 269) | P value   |
|---------------------------------|-------------------------------|-----------------------------------|-------------------------------|-----------|
| Age, years                      | 64.0 ± 4.2                   | 71.6 ± 6.5                        | 73.3 ± 6.5                   | <0.001    |
| Female sex, n (%)               | 36 (14.3)                    | 136 (26.7)                       | 89 (33.1)                    | <0.001    |
| Diabetes mellitus, n (%)        | 58 (23.1)                    | 142 (27.9)                       | 83 (30.9)                    | 0.136     |
| Hypertension, n (%)             | 147 (58.6)                   | 322 (63.3)                       | 156 (58.0)                   | 0.258     |
| Weight, kg                      | 67.8 ± 9.7                   | 61.4 ± 9.8                       | 59.5 ± 9.3                   | <0.001    |
| Time to admission > 4 h, n (%)  | 181 (72.1)                   | 444 (87.2)                       | 244 (90.7)                   | <0.001    |
| Anterior myocardial infarction, n (%) | 78 (31.1)     | 224 (44.0)                       | 169 (62.8)                   | <0.001    |
| SBP, mmHg                       | 127.2 ± 17.7                 | 126.1 ± 20.8                     | 110.7 ± 26.4                 | <0.001    |
| DBP, mmHg                       | 75.6 ± 11.2                  | 73.4 ± 12.4                      | 67.6 ± 14.4                  | <0.001    |
| Heart rate, bpm                 | 76.4 ± 12.5                  | 77.5 ± 13.1                      | 86.3 ± 21.0                  | <0.001    |
| Killip II–IV, n (%)             | 16 (6.4)                     | 145 (28.5)                       | 208 (77.3)                   | <0.001    |
| Serum creatinine, mg/dL         | 1.0 (0.8, 1.1)               | 1.0 (0.8, 1.3)                   | 1.2 (0.9, 1.5)               | <0.001    |
| Hemoglobin, g/L                 | 133.1 ± 140                  | 126.6 ± 15.7                     | 124.4 ± 18.8                 | <0.001    |
| Creatine kinase MB, U/L         | 68.7 (30.4,135.1)            | 57.8 (23.8,135.2)                | 62.8 (21.3,159.6)            | 0.290     |
| ALT, U/L                        | 39.0 (28.4,54.2)             | 42.0 (28.1,65.0)                 | 46.1 (31.0,77.8)             | 0.001     |
| Total bilirubin, mg/dL          | 1.0 ± 0.4                    | 1.0 ± 0.4                        | 1.1 ± 0.6                    | 0.029     |
| LVEF, %                         | 55.0 ± 9.8                   | 52.5 ± 11.0                      | 46.8 ± 12.2                  | <0.001    |
| IABP, n (%)                     | 10 (4.0)                     | 55 (10.8)                        | 76 (28.3)                    | <0.001    |
| Thrombus aspiration, n (%)      | 94 (37.5)                    | 156 (30.6)                       | 82 (30.5)                    | 0.130     |
| Treated vessel, n (%)           | 9 (3.6)                      | 25 (4.9)                         | 19 (7.1)                     | 0.185     |
| Any left main                   | 3 (12.4)                     | 62 (12.2)                        | 27 (10.0)                    |          |
| Multi-vessel                    | 221 (88.0)                   | 422 (82.9)                       | 223 (82.9)                   |          |
| Number of stents                | 13 ± 0.7                     | 1.5 ± 0.8                        | 1.4 ± 0.8                    | 0.073     |
| Hospital stay (days)            | 6 (5.7)                      | 7 (6.10)                         | 9 (6.14)                     | <0.001    |
| In-hospital events              |                              |                                  |                              |           |
| Death                           | 3 (1.2)                      | 17 (3.3)                         | 35 (13.0)                    | <0.001    |
| Cardiac death                   | 3 (1.2)                      | 13 (2.6)                         | 25 (9.7)                     | <0.001    |
| MACEs                           | 14 (5.6)                     | 55 (10.8)                        | 65 (24.2)                    | <0.001    |

SBP, systolic blood pressure; DBP, diastolic blood pressure; ALT, alanine transaminase; LVEF, left ventricular ejection fraction; IABP, intra-aortic balloon pump; MACEs, major adverse clinical events
CI = 1.07–1.27, p < 0.001, Table 3). Other significant risk factors included LVEF and IABP treatment.

Patients were reclassified into four groups according to the cut-off of TIMI risk score and MELD-XI: TIMI risk score ≥7 and MELD-XI ≥13 (n = 99), TIMI risk score ≥7 and MELD-XI < 13 (n = 170), TIMI risk score < 7 and MELD-XI ≥13 (n = 143), and TIMI risk score < 7 and MELD-XI < 13 (n = 617). The in-hospital all-cause mortality (25.3%), cardiac mortality (19.6%) and incidence of MACEs (40.4%) were highest in the group of patients with TIMI risk score ≥7 and MELD-XI ≥13 (both p < 0.001, Fig. 2). The Kaplan–Meier curve showed that a higher accumulative one-year mortality was found in patients with TIMI risk score ≥7 and MELD-XI ≥13 (log-rank = 98.35, p < 0.001, Fig. 3). Multivariate

### Table 2 Multivariable logistic regression analysis for in-hospital death

| Clinical variables | OR   | 95% CI         | P-value |
|--------------------|------|----------------|---------|
| Model 1            |      |                |         |
| TIMI risk score    | 1.22 | 1.07, 1.40     | 0.004   |
| MELD-XI            | 1.09 | 1.04, 1.14     | 0.001   |
| log(creatine kinase MB) | 1.44 | 0.79, 2.61     | 0.236   |
| ALT > 40 U/L       | 1.48 | 0.68, 3.20     | 0.326   |
| LVEF               | 0.98 | 0.96, 1.01     | 0.178   |
| IABP               | 3.69 | 1.85, 7.36     | < 0.001 |
| Model 2            |      |                |         |
| TIMI risk score    | 1.23 | 1.07, 1.41     | 0.003   |
| MELD-XI ≥ 13       | 3.83 | 1.99, 7.40     | < 0.001 |
| log(creatine kinase MB) | 1.63 | 0.88, 3.01     | 0.122   |
| ALT > 40 U/L       | 1.28 | 0.59, 2.76     | 0.527   |
| LVEF               | 0.98 | 0.96, 1.01     | 0.226   |
| IABP               | 3.59 | 1.79, 7.19     | < 0.001 |

### Table 3 Univariate and multivariate Cox survival analysis for one-year mortality

| Clinical variables | Univariate analysis | Multivariable analysis |
|--------------------|---------------------|-----------------------|
| TIMI risk score    | HR 1.35, < 0.001    | HR 1.17, 1.07, 1.27, < 0.001 |
| MELD-XI            | HR 1.09, < 0.001    | HR 1.05, 1.01, 1.08, 0.005 |
| Female sex         | HR 1.15, 0.500      | HR 1.40, 0.94, 2.10, 0.101 |
| Diabetes mellitus  | HR 1.84, 0.002      | HR 1.40, 0.94, 2.10, 0.101 |
| Hypertension       | HR 1.12, 0.558      | HR 1.40, 0.94, 2.10, 0.101 |
| Anemia             | HR 1.38, 0.141      | HR 1.40, 0.94, 2.10, 0.101 |
| log(creatine kinase MB) | HR 1.33, 0.125 | HR 1.40, 0.94, 2.10, 0.101 |
| ALT > 40 U/L       | HR 1.84, 0.004      | HR 1.40, 0.94, 2.10, 0.101 |
| LVEF               | HR 0.94, < 0.001    | HR 0.97, 0.95, 0.99, 0.001 |
| IABP               | HR 6.00, < 0.001    | HR 2.32, 1.45, 3.73, 0.001 |
| Thrombus aspiration| HR 1.04, 0.864      | HR 1.84, 1.45, 3.73, 0.001 |
| LMCA intervention  | HR 1.75, 0.109      | HR 1.84, 1.45, 3.73, 0.001 |

OR, odds ratio; CI, confidence interval; TIMI, Thrombolysis In Myocardial Infarction; MELD-XI, Model for End-stage Liver Disease excluding INR; ALT, alanine transaminase; LVEF, left ventricular ejection fraction; IABP, intra-aortic balloon pump; LMCA, left main coronary artery
analysis revealed that compared with TIMI risk score < 7 and MELD-XI < 13, TIMI risk score ≥ 7 and MELD-XI ≥ 13 were independently associated with in-hospital mortality (OR = 11.06, 95% CI = 4.38–27.96, p < 0.001, Table 4), cardiac (OR = 14.09, 95% CI = 4.59–43.27, p < 0.001, Table 4) and one-year mortality (HR = 4.20, 95% CI = 2.24–7.87, p < 0.001, Table 4).

Discussion

The present study showed that MELD-XI was an independent risk factor for in-hospital and one-year mortality after adjusting for TIMI risk score and other potential confounding factors in elderly patients with STEMI undergoing PCI. To our best knowledge, this study is the first to explore the additional prognostic value of MELD-XI to TIMI risk score. Combining TIMI risk score and MELD-XI exhibited better predictive power for in-hospital death than the TIMI risk score or MELD-XI alone.

Patients with TIMI risk score ≥ 7 and MELD-XI ≥ 13 had the worst prognosis.

The TIMI risk score was first developed in the era of thrombolytic therapy and has high discriminative ability for adverse events in STEMI patients [16]. Wei et al. reported that the AUC of the TIMI risk score for predicting in-hospital mortality was 0.803 [19]. In addition, its discriminative ability was adequate for clinical application in STEMI patients undergoing primary PCI (c-statistic, > 0.8) [20]. Accordingly, this score was also recommended for early risk assessment in STEMI patients in the era of primary PCI [6]. However, its predictive power is insufficient in elderly patients. A previous study showed that the prognostic discrimination and calibration of TIMI risk score for the 30-day mortality was not high in elderly patients with STEMI (AUC = 0.67) [7]. Similar results were found in female patients with STEMI [8]. In our study, the AUC of TIMI risk score for predicting in-hospital death was 0.753. Therefore, it is necessary to identify other risk factors to improve the discriminative ability of TIMI risk score.

The MELD score consists of serum creatinine and bilirubin levels and the international normalized ratio (INR), which is established for patients with end-stage liver disease [21]. MELD-XI excluding INR is a simpler risk model that can simultaneously assess renal and liver function [12]. It has already been validated in other conditions. In patients with heart failure, MELD-XI was related to increased risk of death at the one-year follow-up [22]. The AUC of MELD-XI for predicting adverse events at the one-year follow-up was 0.69 in patients undergoing tricuspid annuloplasty [23]. In critically ill patients, MELD-XI represented organ failure and was associated with in-hospital mortality [24].

Elevated serum creatinine and bilirubin are established risk factors for poor prognosis in STEMI patients [25, 26]. Although MELD is reportedly a predictor of long-term survival in patients with acute coronary syndrome undergoing PCI, the prognostic value of MELD-XI is not yet clear [27]. Therefore, we carried out this study, the results of which showed that MELD-XI has similar predictive power as TIMI risk score in elderly patients with STEMI undergoing PCI. In addition, MELD-XI was associated with in-hospital and 1-year mortality even after adjusting for TIMI risk score and other confounding factors. Renal and hepatic function are not included elements in the TIMI risk score. Accordingly, the combination of MELD-XI and TIMI risk scores showed high predictive power for in-hospital and one-year mortality, which could be a potentially useful tool for risk assessment in elderly patients with STEMI undergoing PCI.
Limitations

The present study has some limitations. First, clinical variables were limited owing to the retrospective study design. Second, although multivariate analysis was conducted, residual confounders might have still affected our results. Third, this study was conducted in elderly patients with STEMI undergoing PCI; therefore, it remains to be seen whether these conclusions can be extrapolated to other age groups. Finally, this study was a single-center study and thus external validity of results has not been measured.

Conclusion

Our study demonstrated that MELD-XI could predict in-hospital and one-year mortality in elderly patients with STEMI undergoing PCI. The discriminative ability of MELD-XI for in-hospital death was equal to that of the TIMI risk score. MELD-XI could provide additional prognostic value to the TIMI risk score. Therefore, it may be clinically useful to combine the MELD-XI and TIMI risk scores for risk assessment in elderly patients with STEMI undergoing PCI.

Abbreviations

MELD-XI: The model for end-stage liver disease excluding international normalized ratio; TIMI: Thrombolysis In Myocardial Infarction; STEMI: ST-segment elevation myocardial infarction; PCI: Percutaneous coronary intervention; AUC: Area under the curve; LVEF: left ventricular ejection fraction; IABP: intra-aortic balloon pump; LMCA: left main coronary artery

Acknowledgments

None.

Author contributions

PCN contributed to the conception or design of the work. HSJ, WJX, CHJ, LHQ, GWQ, CQ, XS and YHB contributed to the acquisition, analysis, or interpretation of data for the work. HSJ and WJX drafted the manuscript. PCN critically revised the manuscript. All gave final approval and agree to be accountable for all aspects of work ensuring integrity and accuracy. All authors read and approved the final manuscript.

Funding

None.

Availability of data and materials

The database used and/or analyzed for this study available from the corresponding author on reasonable request (Chang-nong Peng; Email: 819650730@qq.com).

Ethics approval and consent to participate

The study protocol was approved by the Ethics Committee of Fuwai Hospital Chinese Academy of Medical Sciences (SP2017016), and the need for informed consent was waived given the retrospective nature of the analysis.

Consent for publication

Not Applicable.

Competing interests

The authors declare that they have no competing interests.

Author details

1 Department of Coronary Heart Disease, Fuwai Hospital Chinese Academy of Medical Sciences, Shenzhen, Langshuan Road 12, Shenzhen 518000, China.2 Department of Coronary Heart Disease, Peking University Shenzhen Hospital, 1120 Lianhua St, Futian District, Shenzhen 518000, China.

Received: 19 August 2020 Accepted: 10 January 2021
Published online: 28 January 2021

Table 4 Unadjusted and adjusted OR/HR of different risk

|                          | TIMI risk score ≥ 7 and MELD-XI ≥ 13 | TIMI risk score ≥ 7 and MELD-XI < 13 | TIMI risk score < 7 and MELD-XI ≥ 13 |
|--------------------------|-------------------------------------|-------------------------------------|-------------------------------------|
| In-hospital all-cause death | OR/HR (95% CI) P                     | OR/HR (95% CI) P                     | OR/HR (95% CI) P                     |
| Model 1: unadjusted      | 20.51 (9.48, 44.38) < 0.001          | 3.79 (1.55, 9.27) 0.003             | 4.56 (1.86, 11.19) 0.001             |
| Model 2: multivariate adjusted* | 11.06 (4.38, 27.96) < 0.001          | 2.83 (1.06, 7.57) 0.038             | 3.63 (1.33, 9.87) 0.012             |
| In-hospital cardiac death | 21.09 (8.53, 52.18) < 0.001          | 4.34 (1.55, 12.14) 0.005            | 5.87 (2.15, 16.04) 0.001            |
| Model 2: multivariate adjusted* | 14.09 (4.59, 43.27) < 0.001          | 3.71 (1.16, 11.91) 0.027            | 5.56 (1.74, 17.78) 0.004            |
| One-year death           | 9.58 (5.57, 16.46) < 0.001           | 4.94 (2.89, 8.46) < 0.001           | 5.10 (2.93, 8.89) < 0.001           |
| Model 2: multivariate adjusted# | 4.20 (2.24, 7.87) < 0.001           | 3.48 (1.95, 6.19) < 0.001           | 3.44 (1.88, 6.32) < 0.001           |

TIMI risk score < 7 and MELD-XI < 13 as reference

TIMI, Thrombolysis In Myocardial Infarction; MELD-XI, Model for End-stage Liver Disease excluding INR; ALT, alanine transaminase; LVEF, left ventricular ejection fraction; IABP, intra-aortic balloon pump; LMCA, left main coronary artery

* Adjusted for log(creatine kinase MB), ALT > 40 U/L, LVEF, and IABP

# Adjusted for diabetes mellitus, ALT > 40 U/L, LVEF, and IABP
References

1. Vogel B, Claessen BE, Arnold SV, Chan D, Cohen DJ, Giannitsis E, et al. ST-segment elevation myocardial infarction. Nat Rev Dis Primers. 2019;5:39.
2. Barnett R. Acute myocardial infarction. Lancet. 2019;393:2580.
3. Morici N, Savonitto S, Ferri LA, Grosseto D, Bossi I, Spanzerla P, et al. Outcomes of elderly patients with ST-Elevation or Non-ST-Elevation acute coronary syndrome undergoing percutaneous coronary intervention. Am J Med. 2019;132:209–16.
4. Shehab A, Bhagavathula AS, Alhabib KF, Ullah A, Suwaidi JA, Almahmeed W, et al. Age-related sex differences in clinical presentation, management, and outcomes in ST-segment-elevation myocardial infarction: pooled analysis of 15 532 patients from 7 Arabian gulf registries. J Am Heart Assoc. 2020;9:e13880.
5. Velders MA, James SK, Libungan B, Sarno G, Frobert O, Carlsson J, et al. Prognosis of elderly patients with ST-elevation myocardial infarction treated with primary percutaneous coronary intervention in 2001 to 2011: A report from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR) registry. Am Heart J. 2014;167:666–73.
6. O’Gara PT, Kushner FG, Ascheim DD, Casey DJ, Chung MK, de Lemos JA, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013;61:e78–140.
7. Rathore SS, Wennfurt KP, Foody JM, Krumholz HM. Performance of the Thrombolysis in Myocardial Infarction (TIMI) ST-elevation myocardial infarction risk score in a national cohort of elderly patients. Am Heart J. 2005;150:402–10.
8. Furnaz S, Karim M, Ashraf T, Ali S, Shahid I, Ali S, et al. Performance of the TIMI risk score in predicting mortality after primary percutaneous coronary intervention in elderly women: results from a developing country. PLoS ONE. 2019;14:e20289.
9. Ponnappan S, Ponnappan U. Aging and immune function: molecular mechanisms to interventions. Antioxid Redox Signal. 2011;14:1551–85.
10. Shlipak MG, Heidenreich PA, Noguchi H, Chertow GM, Browner WS, McClellan MB. Association of renal insufficiency with treatment and outcomes after myocardial infarction in elderly patients. Ann Intern Med. 2002;137:555–62.
11. Basta G, Chatzianagnostou K, Paradossi U, Botto N, Del Turco S, Taddei A, Berti S, Mazzone A. The prognostic impact of objective nutritional indices on mortality in elderly patients with ST-elevation myocardial infarction undergoing primary coronary intervention. Int J Cardiol. 2016;221:987–92.
12. Heuman DM, Mihas AA, Habib A, Gilles HS, Stravitz RT, Sanyal AJ, et al. MELD-XI: a rational approach to “sickest first” liver transplantation in cirrhotic patients requiring anticoagulant therapy. Liver Transpl. 2007;13:30–7.
13. Wernly B, Frutos-Vivar F, Perheel H, Raymondos K, Muriel A, Du B, et al. Easy prognostic assessment of concomitant organ failure in critically ill patients undergoing mechanical ventilation. Eur J Intern Med. 2019;70:18–23.
14. Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018;39:119–77.
15. Morrow DA, Antman EM, Charlesworth A, Cairns R, Murphy SA, de Lemos JA, et al. TIMI risk score for ST-elevation myocardial infarction: a convenient, bedside, clinical score for risk assessment at presentation: an intravenous nPA for treatment of infarcting myocardium early II trial substudy. Circulation. 2000;102:2031–7.
16. He PC, Wei XB, Luo SN, Chen XL, Ke ZH, Yu DQ, et al. Risk prediction in infective endocarditis by modified MELD-XI score. Eur J Clin Microbiol Infect Dis. 2018;37:1243–50.
17. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a non-parametric approach. Biometrics. 1988;44:837–45.
18. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a non-parametric approach. Biometrics. 1988;44:837–45.
19. Wei XB, Liu YH, He PC, Jiang L, Zhou YL, Chen JY, et al. Additive prognostic value of left ventricular ejection fraction to the TIMI risk score for inhospital and long-term mortality in patients with ST segment elevation myocardial infarction. J Thromb Thrombolysis. 2017;43:1–6.
20. Gevaert SA, De Bacquier D, Evrard P, Convens C, Dubois P, Boland J, et al. Gender, TIMI risk score and in-hospital mortality in STEMI patients undergoing primary PCI: results from the Belgian STEMI registry. EuroIntervention. 2014;9:1095–101.
21. Kamath PS, Wiesner RH, Malinchoc M, Kremers W, Therneau TM, Kosberg CL, et al. A model to predict survival in patients with end-stage liver disease. Hepatology. 2001;33:464–70.
22. Biegus J, Zymlinski R, Sokolski M, Siwolowski P, Gajewski P, Nawrocka-Milward S, et al. Impaired hepato-renal function defined by the MELD XI score as prognosticator in acute heart failure. Eur J Heart Fail. 2016;18:1518–21.
23. Chen Y, Liu YX, Seto WK, Wu MZ, Yu YJ, Lam YM, et al. Prognostic value of hepaticorenal function by modified model for end-stage liver disease (MELD-XI) score in patients undergoing tricuspid annuloplasty. J Am Heart Assoc. 2018. https://doi.org/10.1161/JAHA.118.009020.
24. Wernly B, Lichtenauer M, Vellinga N, Boerma C, Ince C, Kelm M, et al. Model for End-Stage Liver Disease Excluding INR (MELD-X) score is associated with hemodynamic impairment and predicts mortality in critically ill patients. Eur J Intern Med. 2018;51:80–4.
25. Szummer K, Lundman P, Jacobson SH, Schon S, Lindback J, Stenestrand U, et al. Relation between renal function, presentation, use of therapies and in-hospital complications in acute coronary syndrome: data from the SWEDHEART register. J Intern Med. 2010;268:40–9.
26. Gu M, Uyarel H, Ergelen M, Akgul O, Karaca G, Turen S, et al. Prognostic value of total bilirubin in patients with ST-segment elevation acute myocardial infarction undergoing primary coronary intervention. Am J Cardiol. 2013;111:166–71.
27. Kris T, Avci E, Celik A. Combined value of left ventricular ejection fraction and the Model for End-Stage Liver Disease (MELD) score for predicting mortality in patients with acute coronary syndrome who were undergoing percutaneous coronary intervention. BMC Cardiovasc Disord. 2018;18:44.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.